Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive AdvisorsGlobeNewsWire • 02/10/20
Short-Term Catalyst And Long-Term M&A Potential Make Agile Therapeutics An Attractive Potential Takeover TargetSeeking Alpha • 02/10/20
Agile Therapeutics' Market Potential, And Other News: The Good, Bad, And Ugly Of BiopharmaSeeking Alpha • 02/06/20
Agile: FDA Decision To Extend Twirla's PDUFA Date Provides Buying OpportunitySeeking Alpha • 11/18/19
Agile Therapeutics: Stock Hits 52-Week Low And A Near 52-Week High Around Twirla's AdComSeeking Alpha • 11/06/19
Agile Therapeutics' stock rockets nearly 4-fold after contraceptive patch Twirla gets favorable FDA committee nodMarket Watch • 10/31/19
Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15)GlobeNewsWire • 10/30/19
Is Agile Therapeutics (AGRX) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 10/25/19
Agile Therapeutics (AGRX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 10/25/19
Agile Therapeutics (AGRX) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 09/10/19